Salute e Benessere

Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21…

Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024Halle (Saale) / Munich, Germany, May 08, 2024- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its 2024 Annual General Meeting will be held on Friday, June 21, 2024 at 01:00 p.m...
Nasdaq GlobeNewswire
08/05/2024

Addex to Present at Bio€quity Europe 2024

Geneva, Switzerland, May 8, 2024 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at theBio€quity Europe 2024conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain. In his in-person presentation, scheduled for 14:00 – 14:12 CEST, on Monday May 13, 2024 in Room 6 + 7, Mr. Dyer will provide a corporate...
Nasdaq GlobeNewswire
08/05/2024

DBV Technologies Reports First Quarter 2024 Financial Results and Business…

DBV Technologies Reports First Quarter 2024 Financial Results and Business UpdateVITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with...
Nasdaq GlobeNewswire
07/05/2024

Oculis Publishes Invitation to the Annual General Meeting

/ 9:30 a.m. EDT.All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website athttps://investors.oculis.com/events-presentations. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis' highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for...
Nasdaq GlobeNewswire
07/05/2024

Report of transactions of shares and related securities of Bavarian Nordic by…

COPENHAGEN, Denmark, May 7, 2024– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.The transactions concern grants of restricted stock units as part of the remuneration of the Board of Directors as adopted at the ordinary general meeting on April 16, 2024. Restricted stock units equivalent to the...
Nasdaq GlobeNewswire
07/05/2024

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9…

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Dr. David Koos, in real time. Please ask your questions during the event and Dr. Koos and his team will do their best to get through as many of them as possible. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Dr.David Koos, in real time...
PR Newswire
07/05/2024

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 7, 2024 –Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:2,171 shares at DKK 1,025.00, 2,790 shares at DKK 1,032.00, 98 shares at DKK 1,161.00, 729 shares at...
Nasdaq GlobeNewswire
07/05/2024

EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST…

EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT® Expansion in the oncology segmentDevelopment of Eurobio Scientific proprietary product portfolioIncrease of international exposure Paris, 7 thMay 2024 – 06:30 pmEurobio Scientific(FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, announces the signing on May 7 th, 2024...
Nasdaq GlobeNewswire
07/05/2024

AB Science : A new publication in the medical journal Muscle & Nerve validates…

PRESS RELEASEA NEW PUBLICATION IN THE MEDICAL JOURNALMUSCLE & NERVEVALIDATES THE USE OF THE RATE OF DECLINE OF ALSFRS-R SCORE (ΔFS) FOR THE DESIGN OF CLINICAL STUDIES AND THE TREATMENT CHOICE FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTSTHIS PUBLICATION VALIDATES THE CLINICAL TRIAL DESIGN OF MASITINIB PHASE 2/3 STUDY AB10015 AND CONFIRMATORY STUDY IN ALSParis, May 07, 2024, 6pm CETAB Science SA(Euronext - FR0010557264 - AB) today announced the publication of...
Nasdaq GlobeNewswire
07/05/2024

Groupe Casino - Nombre de droits de vote et d'actions 30-04-2024 / 06-05-2024

CASINO, GUICHARD-PERRACHON Société anonyme au capital de 395 740 444,29 € Siège social : 1, Cours Antoine Guichard 42000 Saint-Etienne 554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de vote et d'actions composant le capital social(article 223-16 du Règlement Général de l'Autorité des Marchés Financiers)6 mai 2024Nombre d'actions composant le capitalNombre total de droits de voteNombre total de droits de vote exerçables en...
Nasdaq GlobeNewswire
07/05/2024

Bulletin from annual general meeting of Enzymatica AB (publ) on May 7, 2024

Income statements and balance sheets Income statements and balance sheets The general meeting resolved to adopt the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet. Disposition of the company's profit or loss The general meeting resolved, in accordance with the board of directors' proposal, that no dividend is paid for the fiscal year 2023 and that the company's funds available for distribution are carried...
PR Newswire
07/05/2024

Philips shareholders approve all proposals at the AGM 2024

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2024, including: The re-appointment of Chairman Feike Sijbesma and Peter Löscher as members of the Supervisory Board.The appointment of Benoît Ribadeau-Dumas as member of the Supervisory Board.The appointment of Charlotte Hanneman as member of the Board of Management, with effect from October 1, 2024...
Nasdaq GlobeNewswire
07/05/2024

NTG Nordic Transport Group publishes interim report for Q1 2024

Company announcement no. 5 – 24 7 May 2024 NTG Nordic Transport Group publishes interim report for Q1 2024The interim report for Q1 2024 is enclosed.In connection with publication of the results for Q1 2024, a conference call will be hosted on 8 May 2023 at 10:00 AM CEST.The conference call will be held in English and can be followed live via NTG's website ; investor.ntg.com. Additional information For additional information, please contact: Investor relations and press:...
Nasdaq GlobeNewswire
07/05/2024

Parenteral Nutrition Bags Market to be Worth $1.25 Billion by 2031 - Exclusive…

Parenteral nutrition bags are used to compound and store potential fluid prior to and during intravascular administration to a patient. By using standard spikes and tubing, the empty bags are filled by attaching them to containers, usually glass bottles that are sealed with a pierceable membrane and hold one or more solutions. Parenteral nutrition replaces lost energy and makes up for micronutrient deficiencies in patients. Parenteral nutrition bags are used to compound and store potential...
PR Newswire
07/05/2024

Portable Ultrasound Market Worth $3.8 billion by 2031 - Exclusive Report by…

Portable ultrasound devices offer a cost-effective, highly mobile, and easy-to-use alternative to traditional cart-based ultrasounds. Point-of-care ultrasound, also known as PoC ultrasound or POCUS, enables physicians to carry out diagnostic imaging near patients. Additionally, advances in handheld ultrasound devices through the integration of artificial intelligence and machine learning are increasing the accuracy of image analysis, leading to better result interpretation. Additionally, the…
PR Newswire
07/05/2024

Veterinary Reference Laboratory Market Worth $7.8 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=256972714 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=256972714 Browse in-depth TOC on "Veterinary Reference Laboratory Market" 268 - Tables 55 - Figures 304 - Pages Veterinary Reference Laboratory Market Scope: Clinical chemistry services segment is expected to account for the largest share, by service type in the veterinary...
PR Newswire
07/05/2024

Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell…

"We're proud to partner with Adva Biotechnology and be the first CDMO in North America to offer the ADVA X3® to clients. The ADVA X3's automation and precision are game changers, enabling us to scale up production and meet the urgent needs of patients," said Michael O'Mara, COO of Cellipont Bioservices. "We're proud to partner with Adva Biotechnology and be the first CDMO inNorth Americato offer the ADVA X3 ®to clients. The ADVA X3's automation and precision are game changers…
PR Newswire
07/05/2024

Seragon Completes Pre-Clinical Study of Aging Intervention Candidate SRN-901

Other tests were conducted to evaluate the effect of SRN-901 on healthspan, a measure of how long health is maintained over the course of one's life. The study also evaluated physical and cognitive function. Treadmill tests showed significantly enhanced endurance in elderly mice. Frailty scores showed marked improvement in the elderly mice receiving SRN-901, and there was a significant reduction in tumor occurrence in the treated group. Other tests were conducted to evaluate the effect of...
PR Newswire
07/05/2024

Pharmaceutical Fine Chemicals Market worth USD 246.5 Billion to 2031 - Exclusive…

Pharmaceutical fine chemicals used in pharmaceutical drug production. It includes a wide range of chemicals, from the active pharmaceutical ingredients (APIs) to the excipients used in drug production. Pharmaceutical fine chemicals used in pharmaceutical drug production. It includes a wide range of chemicals, from the active pharmaceutical ingredients (APIs) to the excipients used in drug production. The pharmaceutical chemical market is anticipated to be driven by the rising demand for...
PR Newswire
07/05/2024

Ipsen S.A. - Formalities for making available and consulting preparatory…

Information relating to the holding of the Combined Shareholders' Meeting of 28 May 2024 of Ipsen S.A.Formalities for making available and consulting preparatory documents to the Meeting BOULOGNE-BILLANCOURT, FRANCE, 7 May 2024 -The Shareholders of the Company are invited to participate in the Combined Shareholders' Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Tuesday 28 May 2024 at 3:00 p.m. (Paris time) at theSalons de l'Hôtel des Arts et Métiers, 9...
Nasdaq GlobeNewswire
07/05/2024

CCELL Disrupts All-In-One Vape Category with New Mini Tank and Atom, Two Ultra…

In addition to CCELL's established customization capabilities for product surface finish styles and secondary features, the Mini Tank also offers multiple possibilities at the component level. Optional components, such as the new EVOMAX heating element and multi-purpose slide switch, allow for four variations of the Mini Tank. In addition to CCELL's established customization capabilities for product surface finish styles and secondary features, the Mini Tank also offers multiple possibilities...
PR Newswire
07/05/2024

Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress…

thInternational Congress of the Growth Hormone Research Society (GRS), which is being held May 10-11 in Stockholm, Sweden, the 26 thEuropean Congress of Endocrinology (ECE), which is being held May 11-14 in Stockholm, Sweden, and at the 2024 Endocrine Society Meeting (ENDO), which is being held June 1-4 in Boston, Massachusetts. These presentations cover both of Amolyt's development programs, eneboparatide in Phase 3 for the treatment of hypoparathyroidism and AZP-3813 in Phase 1 for the...
Nasdaq GlobeNewswire
07/05/2024

Phenomenex Unveils Expanded Product Portfolio to Reduce or Eliminate Background…

The "Designed for PFAS" portfolio includes SPE cartridges in multiple phases and formats to meet laboratory demands for PFAS extraction from aqueous and non-aqueous samples (Strata™ X-AW, Strata PFAS). Additionally, the portfolio includes essential accessories such as HPLC mobile phase safety caps (SecurityCAP™) and vials (Verex™) supporting trace level detection limits thus accurate PFAS analysis. The " Designed for PFAS " portfolio includes SPE cartridges in multiple phases…
PR Newswire
07/05/2024

Golden Helix Secures CE Mark for the European Union

"Obtaining the CE mark is a pivotal step for Golden Helix as we expand internationally," said Dr. Andreas Scherer, President and CEO of Golden Helix. "This approval not only demonstrates our commitment to compliance and quality. It enhances our ability to serve healthcare providers with advanced genetic testing solutions that improve patient outcomes." "Obtaining the CE mark is a pivotal step for Golden Helix as we expand internationally," said Dr.Andreas Scherer…
PR Newswire
07/05/2024
Altri  Comunicati